dots health software glp-1 Points® in the GLP1 Companion Program: Explained Ro launches GLP-1 supply tracker

Clinical trials have shown their efficacy and safety over several years, yet the possibility of long-term adverse effects remains a research focus

The vomiting rate of approximately 21% is particularly notable, as it approaches one in five users

Other research found a promising link between protein intake and GLP-1 secretion

Absorption is more fragile than injections, so timing and consistency matter more with daily oral dosing

Weight loss can help to reduce the risk of developing type 2 diabetes, heart disease, stroke, and other chronic diseases

According to the American Diabetes Association, in 2021, the prevalence of diabetes in the US was 11.6%, affecting 38.4 million Americans